Announcements
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
- BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
More ▼
Key statistics
On Thursday, BridgeBio Pharma Inc (2CL:FRA) closed at 27.79, -30.04% below its 52-week high of 39.72, set on Dec 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.34 |
---|---|
High | 28.34 |
Low | 27.79 |
Bid | -- |
Offer | -- |
Previous close | 27.49 |
Average volume | 1.45k |
---|---|
Shares outstanding | 187.13m |
Free float | 144.90m |
P/E (TTM) | -- |
Market cap | 5.63bn USD |
EPS (TTM) | -3.23 USD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼